The clinical trial process is broken for a variety of reasons, ranging from the difficulty of designing trial protocols to the cost of running them. But one critical (and solvable) issue is finding, ...

Health care is undergoing an important and well-needed shift from a one-size-fits-all approach to more personalized, precise, patient-focused care. A similar approach needs to be implemented at scale ...

The research industry’s approach to building clinical trial equity and inclusion has shifted, bringing a renewed focus to these goals. This is great news: Trials that more accurately represent patient ...

Expanding clinical trial access locally reduces logistical and financial barriers, making participation feasible for underserved populations. Addressing myths about clinical trials helps patients ...

In total, 5,251 discretized criteria were extracted from 216 protocols. The most frequent criterion was previous chemotherapy/biologics (17%). The multilabel SVM demonstrated a pooled accuracy of 75%.

The U.S. Food & Drug Administration (FDA) issued final guidance (Final Guidance) regarding informed consent titled “Informed Consent: Guidance for Institutional Review Boards, Clinical Investigators, ...

The US Food and Drug Administration (FDA) wants the public's feedback on ways it can make it easier to communicate with the agency during the clinical trials process. In an announcement in the Federal ...